# Eli Lilly Sues Multiple Compounding Pharmacies in 2025

Canonical source: https://retacompare.com/research/lilly-sues-pharmacies-2025-114

Eli Lilly · 2026-02-16


    Beyond the major telehealth cases, Eli Lilly filed dozens of actions throughout 2025 against individual compounding pharmacies preparing or distributing compounded tirzepatide. These cases typically target 503A or 503B facilities with demonstrable marketing of tirzepatide as an 'equivalent' or 'alternative' to Lilly's branded products. Many have settled quickly on confidential terms, often including consent injunctions ceasing compounded tirzepatide production and distribution. Other cases have proceeded to contested litigation, contributing to the developing body of case law on compounded peptide disputes.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources